HIV-1 viremia during the first 28 weeks of pregnancy is not associated with mother-to-child transmission
- PMID: 17293908
- DOI: 10.1590/s1413-86702006000400009
HIV-1 viremia during the first 28 weeks of pregnancy is not associated with mother-to-child transmission
Abstract
It is currently recommended that antiretroviral prophylaxis to prevent mother-to-child transmission (MTCT) of HIV be initiated at 14 weeks of gestation. However, the relevance of early-gestation HIV viral load level for intrauterine MTCT is unknown. The objective of this study was to determine the relationship between prenatal maternal viral load and intrauterine MTCT. Records of HIV-infected pregnant women in two centers in Brazil, from 1999 to 2004 were analyzed. Three pregnancy periods were considered: earlier than 14 weeks, 14 to 27 6/7 weeks, and 28 weeks of gestation or more. Peripartum HIV exposure was also computed. Maximum viral load in each period was the measure of HIV exposure. Four hundred fifty-seven HIV-infected pregnant women were evaluated, but 53 were excluded. The MTCT rate was 0.49% (2/404-95% confidence interval (CI95) = 0.14-1.79%). Newborns were not breast-fed. Median viral load for the earlier-than-14-week period was 9,900 copies/mL (P25-75 1,000-50,775 copies/mL), 8,350 copies/mL (P25-75 707-42,000 copies/mL) for the 14 to 27 6/7-week period, and 435 copies/mL (P25-75 90-7,775 copies/mL) after the 28-week period. The peripartum median viral load was 400 copies/mL (P25-75 80-500 copies/mL). MTCT in mothers with VL > 1,000 copies/mL during the first 14 weeks (0.67%, 2/298) was not different from those with VL =1,000 copies/mL (0.0%, 0/96, P=1). Analogously, in the 14 to 27 6/7-week period, MTCT was similar in groups with VL higher (0.68%, 2/292) or lower (0%, 0/106) than 1,000 copies/mL (P=1). Regarding VL >1,000 copies/mL at 28-weeks-or-later and at peripartum periods, MTCT rates were 1.15% (2/173, P = 0.18) and 2.8% (2/71, P = 0.03), respectively. Intrauterine transmission does not seem to be influenced by HIV viremia during the first 28 weeks of pregnancy.
Similar articles
-
Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort.AIDS. 2008 Jan 11;22(2):289-99. doi: 10.1097/QAD.0b013e3282f3d63c. AIDS. 2008. PMID: 18097232
-
[Factors associated with virological response in women receiving highly-active antiretroviral prophylaxis for HIV-1 mother-to-child transmission].Enferm Infecc Microbiol Clin. 2008 Aug-Sep;26(7):411-5. doi: 10.1157/13125637. Enferm Infecc Microbiol Clin. 2008. PMID: 18842235 Spanish.
-
HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa.HIV Med. 2017 Feb;18(2):80-88. doi: 10.1111/hiv.12397. Epub 2016 Jun 28. HIV Med. 2017. PMID: 27353189
-
Mother-to-child transmission of HIV-1: advances and controversies of the twentieth centuries.AIDS Rev. 2004 Apr-Jun;6(2):67-78. AIDS Rev. 2004. PMID: 15332429 Review.
-
Prevention of perinatal HIV transmission during pregnancy.J Antimicrob Chemother. 2000 Nov;46(5):657-68. doi: 10.1093/jac/46.5.657. J Antimicrob Chemother. 2000. PMID: 11062184 Review.
Cited by
-
Mother-to-child transmission of human immunodeficiency virus in aten years period.Reprod Health. 2011 Nov 30;8:35. doi: 10.1186/1742-4755-8-35. Reprod Health. 2011. PMID: 22129112 Free PMC article.
-
Short communication: Use of raltegravir in late-presenting HIV-infected pregnant women.AIDS Res Hum Retroviruses. 2013 Nov;29(11):1451-4. doi: 10.1089/AID.2013.0059. Epub 2013 Jun 25. AIDS Res Hum Retroviruses. 2013. PMID: 23731224 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical